 MAP Kinase Kinase 2
"MAP Kinase Kinase 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 44 kDa mitogen-activated protein kinase kinase with specificity for MITOGEN-ACTIVATED PROTEIN KINASE 1 and MITOGEN-ACTIVATED PROTEIN KINASE 3.
| Descriptor ID |
D048370
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.565.200 D08.811.913.696.620.682.725.200.200 D12.644.360.440.200 D12.776.476.440.200
|
| Concept/Terms |
MAP Kinase Kinase 2- MAP Kinase Kinase 2
- MAP2K2 Protein
- MAPK Extracellular Signal-Regulated Kinase 2
- MAPK Extracellular Signal Regulated Kinase 2
- MAPK Kinase 2
- MEK-2 (MAPK Extracellular Signal-Regulated Kinase 2)
- MEK2 (MAPK Extracellular Signal-Regulated Kinase 2)
- Mitogen-Activated Protein Kinase Kinase 2
- Mitogen Activated Protein Kinase Kinase 2
- Kinase Activator Kinase MEK2
- MAPK-ERK Kinase 2
- MAPK ERK Kinase 2
|
Below are MeSH descriptors whose meaning is more general than "MAP Kinase Kinase 2".
Below are MeSH descriptors whose meaning is more specific than "MAP Kinase Kinase 2".
This graph shows the total number of publications written about "MAP Kinase Kinase 2" by people in UAMS Profiles by year, and whether "MAP Kinase Kinase 2" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2019 | 0 | 1 | 1 | | 2017 | 1 | 0 | 1 | | 2015 | 0 | 1 | 1 | | 2008 | 0 | 2 | 2 | | 2006 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "MAP Kinase Kinase 2" by people in Profiles over the past ten years.
-
Arend RC, Davis AM, Chimiczewski P, O'Malley DM, Provencher D, Vergote I, Ghamande S, Birrer MJ. EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer. Gynecol Oncol. 2020 02; 156(2):301-307.
-
Zawistowski JS, Bevill SM, Goulet DR, Stuhlmiller TJ, Beltran AS, Olivares-Quintero JF, Singh D, Sciaky N, Parker JS, Rashid NU, Chen X, Duncan JS, Whittle MC, Angus SP, Velarde SH, Golitz BT, He X, Santos C, Darr DB, Gallagher K, Graves LM, Perou CM, Carey LA, Earp HS, Johnson GL. Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex. Cancer Discov. 2017 03; 7(3):302-321.
-
Lam H, Dare S, Nguyen T, Austin T. Anesthesia for a pediatric patient with cardiofaciocutaneous syndrome. A A Case Rep. 2015 Apr 01; 4(7):95-6.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|